Title:
COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
Document Type and Number:
Japanese Patent JP2023109968
Kind Code:
A
Abstract:
To provide T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens.SOLUTION: Provided is an isolated recombinant nucleic acid molecule encoding a T-cell receptor (TCR) fusion protein (TFP). The TFP comprises: (a) a TCR subunit comprising (i) at least a portion of a TCR extracellular domain, and (ii) a TCR intracellular domain comprising a stimulatory domain from an intracellular signaling domain selected from the group consisting of CD3 epsilon, CD3 gamma, CD3 delta, TCR alpha, and TCR beta; and (b) a binding ligand or a fragment thereof that is capable of binding to an antibody or fragment thereof. The TCR subunit and the binding ligand are operatively linked. The TFP incorporates into a TCR when expressed in a T-cell.SELECTED DRAWING: Figure 1B
Inventors:
PATRICK BAEUERLE
ROBERT HOFMEISTER
ROBERT HOFMEISTER
Application Number:
JP2023087484A
Publication Date:
August 08, 2023
Filing Date:
May 29, 2023
Export Citation:
Assignee:
TCR2 THERAPEUTICS INC
International Classes:
C12N15/62; A61K31/7105; A61K31/712; A61K31/7125; A61K35/12; A61K35/17; A61K35/76; A61K35/761; A61K48/00; A61P1/04; A61P1/14; A61P3/00; A61P3/10; A61P9/10; A61P31/00; A61P35/00; A61P35/02; A61P37/04; A61P37/06; C07K14/705; C07K16/00; C07K19/00; C12N5/0783; C12N5/10; C12N15/12; C12N15/13; C12N15/63
Attorney, Agent or Firm:
Osamu Yamamoto
Toru Miyamae
Junichi Matsuo
Takumi Terachi
Toru Miyamae
Junichi Matsuo
Takumi Terachi